Clinical Trials Logo
  1. Home
  2. Urea Cycle Disorders
  3. NCT01549015

Study in Healthy Subjects, Patients With Urea Cycle Disorders (UCD) and Carriers of UCD Mutations to Evaluate Urea Cycle Function

Urea Cycle Disorders Clinical Trial

Official title:
Open, Prospective, Diagnostic, Multicentre Study in Healthy Subjects, Patients With Urea Cycle Disorders (UCD), and Carriers of UCD Mutations, to Evaluate in Vivo Ureagenesis Measured After a Single Application of Sodium [1,2-13C]-Acetate

Clinical Trial Summary

This diagnostic study will be performed to investigate the performance of the urea cycle in healthy subjects, asymptomatic carriers of Urea Cycle Disorders (UCD) mutations and subjects with genetically proven urea cycle disorders. The ureagenesis rate will be measured by 13C incorporation assay, a method for in vivo measurement of urea cycle performance with stable isotopes.

Clinical Trial Description

In this diagnostic study CCD09, the urea metabolism in UCD subjects (patients and carriers) and healthy subjects of different age and sex will be assessed by measurement of the incorporation of 13C from orally taken sodium [1,2-13C]-acetate into urea by 13C stable isotope ratio detection. The aim of the study is to determine the 13C urea production and to quantify the total urea production in healthy subject, gene defect carrier or patient as marker for the functioning of the urea cycle. Since there are still only few data available using this specific method for measurement of urea cycle performance, the aim of this study CCD09 is to gain additional results on the 13C assay. To this end, comparison will be made between 13C urea production observed in healthy subjects, UCD patients, and asymptomatic mutation carriers.

An evaluation of this study may also enable the treating physician to better judge the severity of disease and the future risk of metabolic decompensations in patients as well as the potential risk for so far asymptomatic carriers. ;

Study Design

Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01549015
Study type Interventional
Source Cytonet GmbH & Co. KG
Contact
Status Completed
Phase N/A
Start date January 2012
Completion date March 2013
View Details
See also
  Status Clinical Trial Phase
Completed NCT02252770 - Nitric Oxide Supplementation in Argininosuccinic Aciduria N/A
Completed NCT01002469 - Study to Evaluate 13 C Isotope Ratio Measurement for Urea Cycle Capacity Assessment N/A
Completed NCT00986895 - A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group Phase 1
Completed NCT01257737 - To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs) Phase 4
Recruiting NCT05671666 - Ureagenesis Analysis in Healthy Subjects and in Urea Cycle Disorder Patients N/A
Completed NCT02311283 - Pilot Study: Urea Cycle Disorders Practice Patterns and Outcomes Assessment N/A
Completed NCT02489292 - Study to Evaluate the Efficacy of HepaStem in Urea Cycle Disorders Paediatric Patients (HEP002) Phase 2
Completed NCT00992459 - Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders Phase 3
Completed NCT00551200 - Dose-Escalation Safety Study of HPN-100 to Treat Urea Cycle Disorders Phase 2
Completed NCT00947297 - Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD) Phase 3
Completed NCT02740153 - PCORI Urea Cycle Disorder Study
Completed NCT02051049 - Long-term Safety Follow-up Study of Patients Having Received HepaStem (SAF001)
Completed NCT01765283 - Safety Study of HepaStem for the Treatment of Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN) Phase 1/Phase 2
Completed NCT00947544 - Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders Phase 2
Completed NCT01347073 - Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs) Phase 3
Completed NCT00718627 - Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders Phase 2
Completed NCT03797131 - Clinical Food Study to Evaluate the Effect of KB195 on Gut Nitrogen Metabolism in Patients With Urea Cycle Disorders N/A
Terminated NCT01541722 - Oxidative Stress, Inflammation and Acute Decompensation in Urea Cycle Disorders N/A
Completed NCT00345605 - Arginine and Buphenyl in Patients With Argininosuccinic Aciduria (ASA), a Urea Cycle Disorder Phase 2
Recruiting NCT00237315 - Longitudinal Study of Urea Cycle Disorders